electroCore, Inc. (NASDAQ:ECOR – Get Free Report) Director Thomas J. Errico bought 10,000 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were purchased at an average cost of $4.77 per share, with a total value of $47,700.00. Following the completion of the acquisition, the director now owns 266,401 shares in the company, valued at approximately $1,270,732.77. This represents a 3.90% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
electroCore Stock Performance
electroCore stock opened at $4.95 on Friday. The company’s fifty day moving average price is $6.81 and its 200 day moving average price is $11.98. electroCore, Inc. has a 1 year low of $4.47 and a 1 year high of $19.49. The stock has a market capitalization of $36.73 million, a P/E ratio of -2.70 and a beta of 0.92.
electroCore (NASDAQ:ECOR – Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. electroCore had a negative net margin of 54.40% and a negative return on equity of 154.45%. The firm had revenue of $6.72 million for the quarter, compared to analysts’ expectations of $6.93 million. Sell-side analysts predict that electroCore, Inc. will post -1.49 EPS for the current year.
Institutional Investors Weigh In On electroCore
Analysts Set New Price Targets
Several equities analysts have recently weighed in on ECOR shares. LADENBURG THALM/SH SH cut their target price on shares of electroCore from $28.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of electroCore in a report on Thursday, March 13th.
View Our Latest Stock Report on electroCore
About electroCore
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
- Five stocks we like better than electroCore
- What is MarketRank™? How to Use it
- Walmart Stock Alert: Big Price Move Expected Soon
- Why is the Ex-Dividend Date Significant to Investors?
- An Acquisition Just Made Dick’s the Most Exciting Stock in Retail
- What Are Growth Stocks and Investing in Them
- Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.